Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Aufgrund von Vorbereitungen auf eine neue Version von KOPS, können kommenden Montag und Dienstag keine Publikationen eingereicht werden. (Due to preparations for a new version of KOPS, no publications can be submitted next Monday and Tuesday.)
| Type of Publication: | Journal article |
| Publication status: | Published |
| Author: | Stemmer, Kerstin; Finan, Brian; DiMarchi, Richard D.; Tschöp, Matthias H.; Müller, Timo D. |
| Year of publication: | 2020 |
| Published in: | Advanced Drug Delivery Reviews ; 159 (2020). - pp. 34-53. - Elsevier. - ISSN 0169-409X. - eISSN 1872-8294 |
| Pubmed ID: | 32485206 |
| DOI (citable link): | https://dx.doi.org/10.1016/j.addr.2020.05.008 |
| Summary: |
Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.
|
| Subject (DDC): | 570 Biosciences, Biology |
| Keywords: | Incretins; Lipoproteins; Dyslipidemia; Diabetes; Obesity |
| Bibliography of Konstanz: | Yes |
| Refereed: | Yes |
Cite This
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
STEMMER, Kerstin, Brian FINAN, Richard D. DIMARCHI, Matthias H. TSCHÖP, Timo D. MÜLLER, 2020. Insights into incretin-based therapies for treatment of diabetic dyslipidemia. In: Advanced Drug Delivery Reviews. Elsevier. 159, pp. 34-53. ISSN 0169-409X. eISSN 1872-8294. Available under: doi: 10.1016/j.addr.2020.05.008
@article{Stemmer2020Insig-52377, title={Insights into incretin-based therapies for treatment of diabetic dyslipidemia}, year={2020}, doi={10.1016/j.addr.2020.05.008}, volume={159}, issn={0169-409X}, journal={Advanced Drug Delivery Reviews}, pages={34--53}, author={Stemmer, Kerstin and Finan, Brian and DiMarchi, Richard D. and Tschöp, Matthias H. and Müller, Timo D.} }
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/52377"> <dc:creator>Tschöp, Matthias H.</dc:creator> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dc:contributor>Müller, Timo D.</dc:contributor> <dcterms:abstract xml:lang="eng">Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.</dcterms:abstract> <dc:creator>Müller, Timo D.</dc:creator> <dc:contributor>Stemmer, Kerstin</dc:contributor> <dc:creator>Stemmer, Kerstin</dc:creator> <dc:contributor>Tschöp, Matthias H.</dc:contributor> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/52377"/> <dcterms:issued>2020</dcterms:issued> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-01-13T10:53:47Z</dcterms:available> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-01-13T10:53:47Z</dc:date> <dc:creator>DiMarchi, Richard D.</dc:creator> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dc:creator>Finan, Brian</dc:creator> <dc:language>eng</dc:language> <dc:contributor>Finan, Brian</dc:contributor> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:contributor>DiMarchi, Richard D.</dc:contributor> <dcterms:title>Insights into incretin-based therapies for treatment of diabetic dyslipidemia</dcterms:title> </rdf:Description> </rdf:RDF>
This item appears in the following Collection(s)
Search KOPS
Browse
My Account
